We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
51
3 active
Approvals
7
Total approvals
Agencies
1
Regulatory bodies
Founded
N/A
Active, not recruiting
3
5.9%
Completed
46
90.2%
Recruiting
2.0%
Terminated
NMPA
National Medical Products Administration
- Kiora Pharmaceuticals initiated two Phase 2 clinical trials for retinal diseases, including KLARITY for KIO-104 treating retinal inflammation and ABACUS-2 for KIO-301 targeting vision restoration in retinitis pigmentosa patients. - The company secured a strategic partnership with Senju Pharmaceutical for KIO-301 development in Asia, potentially worth up to $110 million plus royalties, while extending KIO-104 market exclusivity to 2043. - With $20.7 million in cash and projected runway into late 2027, Kiora maintains funding beyond anticipated data readouts for both trials while actively recruiting patients across multiple sites.
